Prognostic factors and treatment of patients with advanced synovial sarcoma: A single-center experience

• DOI: 10.4103/ijc.ijc_169_17
• Publication Date: 2017-12-21T05:43:22Z
• Authors: O Ates; S Aksoy; H Yeter; V Sunar; N Kertmen; O Dizdar; A Turker; A Kars
• Keywords: Single Center; Regimen; Progression-free survival

Synovial sarcoma (SS) is a malignant mesenchymal tumor, which comprises 5%-10% of all the sarcomas. There insufficient information on prognostic factors and salvage treatments advanced SS. In this study, we aimed to further clarify clinicopathological features, factors, treatment modalities in SS.A total 45 SS patients followed up between 2001 2015 at our cancer institute, Department Medical Oncology, were retrospectively evaluated. Eleven initially metastatic, remaining developed metastasis or became inoperable due locally disease. Overall survival was evaluated by Kaplan-Meier analysis.The median age 37 (17-70) years 60% (n = 26) them female. most commonly localized lower extremity abdomen-pelvis (29% 29%, respectively). Median follow-up time 33 (6-175) months. Patients treated with two (1-5) line chemotherapies metastatic stage. Ifosfamide plus adriamycin (IMA) (49%, n 22) cisplatin-etoposide (13%, 6) often used chemotherapy regimen as first Partial response obtained 32% IMA chemotherapy. Furthermore, progression-free 6 (1-123) stage diagnosis 21 months (14-27) (12-29) (P 0.53), respectively. Most locations lung (75%) bone. Factors influencing evaluated; statistically significant longer observed metastasis, primary tumor size smaller than 10 cm, who underwent surgery for development-to-metastasis period 12 months.Median Lung common site.